Former CR Bard executives found guilty
This article was originally published in Clinica
Executive Summary
Three former CR Bard executives were found guilty on August 24th of conspiring to defraud the US FDA in connection with faulty catheters. Acting US Attorney Jonathan Chiel said that evidence presented during the eight-week trial demonstrated that from 1987 to early 1990, Bard - at the direction of the three defendants - unlawfully sold and distributed heart catheters which had not been approved by the FDA for human use. Sentencing is scheduled for November 1st: each defendant faces up to five years' imprisonment and a fine of $250,000.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.